December 1, 2025
Fresenius Launches Denosumab Biosimilars in EU
Fresenius announced today the launch of its denosumab biosimilars, Conexxence®1 (denosumab) and Bomyntra®2 (denosumab), in Europe.
These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia®3 (denosumab) and Xgeva®4 (denosumab), respectively.
“Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma.
This milestone marks the next step in the company’s ambition to drive accessibility to high-quality biosimilar therapies, with multiple molecules in early and late-stage development. By continuing its successful track record in the biosimilars space, Fresenius further strengthens its (Bio)Pharma platform, a key pillar of the #FutureFresenius strategy.
1. Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
2. Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
3. Prolia® is a registered trademarks of Amgen Inc.
4. Xgeva® is a registered trademarks of Amgen Inc.